*September 2025*
A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy.
The study showed that continuing osimertinib with the addition of platinum-pemetrexed chemotherapy was associated with improved progression-free survival (PFS) compared with placebo plus chemotherapy (HR: 0.43; 95% CI: 0.27–0.70); median PFS was 8.4 months with osimertinib plus chemotherapy vs. 4.4 months with placebo plus chemotherapy. Median overall survival (OS) was also longer with osimertinib plus chemotherapy (15.9 months) vs. placebo plus chemotherapy (9.8 months) (HR: 0.71; 95% CI: 0.42–1.23).
Note to reader: Trial results indicate that median PFS was 8.4 vs 4.4 months with the drug combination vs placebo plus chemotherapy respectively, a difference of +4 months. The median OS was 15.9 vs 9.8 months with drug combination vs placebo and chemotherapy respectively,.a difference of + 6.1 months.
Read more: https://www.iaslc.org/iaslc-news/press-release/compel-study-shows-continuing-osimertinib-treatment-through-progression
